Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 604 participants.

Also called NCT02855684

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 604 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02855684
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02855684. Randomized; no masking; primary purpose treatment. Start 2016-08-24 (registry gives no type); primary completion 2018-08-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
Acronym
EDITION AP
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine (U300)
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Non-insulin antihyperglycemic drugs
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02855684
Content hash
b0ebbe63c8a89b3fa98a16790842f9d4b1cc1023f28e8473a69086405c0ae530